RTP Mobile Logo


Module 1: Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS)

Track 1: Multidisciplinary considerations in the management of localized uLMS
Track 2: Selection of adjuvant therapy for localized uLMS
Track 3: Case (Dr Leitao): A woman in her late 50s undergoes total abdominal hysterectomy and bilateral salpingo-oophorectomy and is found to have an 8.9-cm, high-grade uLMS with negative margins
Track 4: Use of nomograms to estimate overall survival probability after surgery for localized uLMS
Track 5: Role of neoadjuvant chemotherapy or radiation therapy for patients with large but localized uLMS
Track 6: Initial therapeutic approach for patients with uLMS and a solitary hepatic lesion
Track 7: Case (Dr Leitao): A woman in her mid-40s with vaginal bleeding and an enlarged uterus for whom CT reveals a large uterine mass and a single lesion in the right hepatic lobe is diagnosed with uLMS
Track 8: Consideration of adjuvant endocrine therapy for localized uLMS
Track 9: Appropriate role of minimally invasive surgery for uLMS

Module 2: Sequence and Selection of Currently Available Therapeutic Options for Metastatic uLMS; Future Directions

Track 10: Implications of the negative results of the Phase III ANNOUNCE trial of doxorubicin/olaratumab versus doxorubicin alone for patients with advanced unresectable or metastatic soft tissue sarcoma
Track 11: Therapeutic options for patients with metastatic, high-grade uLMS
Track 12: Case (Dr Secord): A woman in her 30s undergoes total laparoscopic hysterectomy and bilateral salpingo-oophorectomy for high-grade uLMS and receives adjuvant doxorubicin followed by pelvic radiation therapy
Track 13: Clinical experience with pazopanib
Track 14: Second-line treatment options for patients with metastatic uLMS
Track 15: Third-line treatment options for patients with metastatic uLMS
Track 16: Clinical experience with trabectedin for metastatic uLMS
Track 17: Potential role of next-generation sequencing in prioritizing protocol and nonresearch treatment for patients with metastatic uLMS
Track 18: Case (Dr Secord): A woman in her 50s with Stage IV uLMS
Track 19: Case (Dr Van Tine): A woman in her mid-40s with metastatic uLMS receives second-line olaratumab/doxorubicin and third-line trabectedin on clinical trials
Track 20: Activity of ipilimumab/nivolumab in metastatic uLMS
Amanda Nickles Fader, MD
Associate Professor and Director
The Kelly Gynecologic Oncology Service
Center for Rare Gynecologic Cancers
Johns Hopkins School of Medicine
Baltimore, Maryland
Mario M Leitao Jr, MD
Attending Surgeon and Member, Division of Gynecology
Weill Cornell Medical College
Gynecologic Oncology Fellowship Program
Minimal Access and Robotic Surgery Program
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, New York

Angeles Alvarez Secord, MD, MHSc
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Brian A Van Tine, MD, PhD
Medical Oncology
Associate Professor of Medicine
Sarcoma Program Director
Washington University in St Louis
Siteman Cancer Center
St Louis, Missouri
Neil Love, MD
Research To Practice
Miami, Florida